

CEO & BOARD MEMBER

20+ Years of Leading Life Sciences Strategy & Innovation



CHRISTINE ANN MILLER

(973) 610-5092

MillerC@nyc.rr.com

linkedin.com/in/ChristineMiller95

New York, NY

Christine Ann Miller is a forward-thinking, transformational leader who has dedicated her career to establishing clinical, operational, and commercial excellence across the pharmaceutical lifecycle. From the potential of a promising molecule to successful market launch and equitable access for all, she builds strategies and teams that are fit for the purpose of helping people live better lives.

Christine simultaneously advances innovation and excellence by:

- **Establishing Clear Vision, Mission, and Strategy** – Christine leverages her diverse background spanning chemical engineering, R&D operations, and product development, business development, and commercialization, to engage key stakeholders around a common goal of developing innovative solutions for complex problems.

- **Driving Robust Performance Outcomes** – Across both mid and large-cap global pharmaceutical companies, Christine has owned P&Ls of \$100M+ and

pipelines of \$3B in development and acquired products to meet and exceed portfolio targets while positively impacting patients.

- **Building High-performing Teams** – Christine cultivates high-performing cultures by putting people first. Her approach allows companies to identify, attract, and place the right people in the right roles, assembling teams that are “fit for purpose,” whether they are developing, acquiring, or commercializing drugs.

In her current role as President and CEO of Melinta Therapeutics, a company owned by Deerfield Management, Christine is accelerating its transformation, redefining the portfolio from pure play antibiotics to become a leader in the acute care space. She has defined 4 strategic priorities to navigate the company through the transition to a new vision, mission, strategy, and culture. Under Christine’s leadership, the company is executing on a strategic plan focused on building a profitable and sustainable business model that has resulted in profitability with a 60%+ revenue growth, 94% employee engagement, and revenue and EBITDA performance surpassing 2022 targets.

With 3 progressive leadership roles culminating in Global Head of Portfolio – Enterprise at Sandoz, a \$10B division of Novartis, Christine managed the company’s global and U.S. product portfolio. While building the branded generics business, she spearheaded a shift toward rapid-growth and higher-margin segments, including complex generics and value-added medicines. She built a robust 5-year product development and acquisition pipeline, with 20 different product acquisitions, and launched more than 50 new products.

Previously, Christine advanced through the ranks at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals, where she led numerous product launches and held leadership roles in R&D operations and strategic purchasing. She started her career with Merck as a Chemical Engineer and Senior Analyst, Procurement.

Christine is a Board Director for Iveric Bio, an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases. She serves on the R&D and Nominating & Corporate Governance Committees. She also Chairs the Committee for Business Development & Strategy, advising the business through the completion of its second Phase II clinical study for geographic atrophy and NDA filing, with a PDUFA goal date in Q3’23.

Recently, Christine was named the Board Chair of the Antimicrobials Working Group (AWG), an industry-led, 501(c)(6) comprised of emerging antimicrobials and diagnostics companies. She also serves on the board of BioNJ and is an advisory board member of the Healthcare Businesswomen’s Association (HBA) and the Lighthouse Guild.

Christine holds an MBA and a Master’s in Technology Management from the Stevens Institute of Technology, where she now sits on the President’s Leadership Council. Christine earned a Bachelor’s degree in Chemical Engineering from Rensselaer Polytechnic Institute.